Key result
NT-proBNP (AUC 0.87; OR 3.23, p=0.007) and copeptin (AUC 0.84; OR 2.33, p=0.001) independently predicted HF, though only NT-proBNP correlated with systolic dysfunction severity (OR 2.12, p=0.001).
Why the study?
The comparative diagnostic and predictive capacities of NT proBNP and copeptin in HF and their respective associations with the severity of systolic dysfunction needed evaluation.
Do serum NT-proBNP and copeptin accurately diagnose heart failure and predict the severity of systolic dysfunction compared to healthy controls?
Case-Control (n=120)
Do serum NT-proBNP and copeptin accurately diagnose heart failure and predict the severity of systolic dysfunction compared to healthy controls?
Answers are grounded in this paper and cite their sources.
NT-proBNP and copeptin provide complementary diagnostic value in heart failure, with NT-proBNP strongly reflecting systolic dysfunction severity and copeptin offering higher sensitivity.
Objective: To evaluate and compare the diagnostic and predictive capacities of N-terminal pro-B-type natriuretic peptide (NT proBNP) and copeptin in heart failure (HF), and to determine their respective associations with the severity of systolic dysfunction. Methods: A case-control study enrolled 60 patients with diagnosed HF and 60 healthy controls. Serum NT proBNP and copeptin were quantified using enzyme-linked immunosorbent assays. Diagnostic performance was assessed by receiver operating characteristic (ROC) curve analysis. Binary and ordinal logistic regression models identified independent predictors of HF and its severity. Results: Both biomarkers showed good diagnostic accuracy. NT proBNP yielded an area under the curve (AUC) of 0.87 (specificity 99.0%, sensitivity 64.0%), while copeptin produced an AUC of 0.84 (sensitivity 81.9%, specificity 74.0%). Binary logistic regression confirmed both markers as significant independent predictors of HF (NT proBNP: odds ratio [OR] 3.23, p=0.007; copeptin: OR 2.33, p=0.001). Ordinal logistic regression revealed that only NT proBNP maintained a statistically significant association with the severity of systolic dysfunction (OR 2.12, p=0.001), whereas copeptin did not (OR 0.99, p=0.87). Conclusions: NT proBNP and copeptin provide complementary diagnostic information. NT proBNP correlates strongly with cardiac dysfunction severity, whereas copeptin offers enhanced sensitivity to neurohormonal stress. A multimarker strategy may optimise clinical evaluation in HF.
No takes yet. Share an insight, caveat, or question.
Zidan et al. (2026) conducted a case-control in Heart failure and systolic dysfunction (n=120). Serum NT-proBNP and copeptin vs. Healthy controls was evaluated on Diagnosis of heart failure and severity of systolic dysfunction (OR 3.23, p=0.007). NT-proBNP (AUC 0.87; OR 3.23, p=0.007) and copeptin (AUC 0.84; OR 2.33, p=0.001) independently predicted HF, though only NT-proBNP correlated with systolic dysfunction severity (OR 2.12, p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: